WARFARIN SODIUM- warfarin sodium tablet

Страна: США

мова: англійська

Джерело: NLM (National Library of Medicine)

Активний інгредієнт:

WARFARIN SODIUM (UNII: 6153CWM0CL) (WARFARIN - UNII:5Q7ZVV76EI)

Доступна з:

Unit Dose Services

ІПН (Міжнародна Ім'я):

WARFARIN SODIUM

Склад:

WARFARIN SODIUM 2.5 mg

Адміністрація маршрут:

ORAL

Тип рецепту:

PRESCRIPTION DRUG

Терапевтичні свідчення:

Warfarin sodium tablets,USP are indicated for: - Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). - Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. - Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets, USP have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. Warfarin sodium tablets are contraindicated in: - Pregnancy Warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high

Огляд продуктів:

Product: 50436-6360 NDC: 50436-6360-1 30 TABLET in a BOTTLE

Статус Авторизація:

Abbreviated New Drug Application

інформаційний буклет

Unit Dose Services
----------
MEDICATION GUIDE
Warfarin (WAR far in) Sodium Tablets, USP
Read this Medication Guide before you start taking warfarin sodium and
each time you get a refill. There
may be new information. This Medication Guide does not take the place
of talking to your healthcare
provider about your medical condition or treatment. You and your
healthcare provider should talk about
warfarin sodium when you start taking it and at regular checkups.
What is the most important information I should know about warfarin
sodium?
Warfarin sodium can cause bleeding which can be serious and sometimes
lead to death. This is because
warfarin sodium is a blood thinner medicine that lowers the chance of
blood clots forming in your body.
•
You may have a higher risk of bleeding if you take warfarin sodium
and:
• are 65 years of age or older
• have a history of stomach or intestinal bleeding
• have high blood pressure (hypertension)
• have a history of stroke, or "mini-stroke" (transient ischemic
attack or TIA)
• have serious heart disease
• have a low blood count or cancer
• have had trauma, such as an accident or surgery
• have kidney problems
• take other medicines that increase your risk of bleeding,
including:
• a medicine that contains heparin
• other medicines to prevent or treat blood clots
• nonsteroidal anti-inflammatory drugs (NSAIDs)
• take warfarin sodium for a long time. Warfarin sodium, USP is the
active ingredient in warfarin
sodium.
Tell your healthcare provider if you take any of these medicines. Ask
your healthcare provider if you are
not sure if your medicine is one listed above.
Many other medicines can interact with warfarin sodium and affect the
dose you need or increase
warfarin sodium side effects. Do not change or stop any of your
medicines or start any new medicines
before you talk to your healthcare provider.
Do not take other medicines that contain warfarin sodium while taking
warfarin sodium.
•
Get your regular blood test to check for your response to warfari

Характеристики продукта

WARFARIN SODIUM- WARFARIN SODIUM TABLET
UNIT DOSE SERVICES
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
WARFARIN SODIUM SAFELY AND EFFECTIVELY. SEE
FULL PRESCRIBING INFORMATION FOR WARFARIN SODIUM.
WARFARIN SODIUM TABLETS, USP
INITIAL U.S. APPROVAL: 1954
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WARNING: BLEEDING RISK
WARFARIN SODIUM CAN CAUSE MAJOR OR FATAL BLEEDING.(5.1)
PERFORM REGULAR MONITORING OF INR IN ALL TREATED PATIENTS. (2.1)
DRUGS, DIETARY CHANGES, AND OTHER FACTORS AFFECT INR LEVELS ACHIEVED
WITH WARFARIN SODIUM THERAPY. (7)
INSTRUCT PATIENTS ABOUT PREVENTION MEASURES TO MINIMIZE RISK OF
BLEEDING AND TO REPORT SIGNS AND
SYMPTOMS OF BLEEDING. (17)
INDICATIONS AND USAGE
Warfarin sodium tablets, USP are a vitamin K antagonist indicated for:
Prophylaxis and treatment of venous thrombosis and its extension,
pulmonary embolism (1)
Prophylaxis and treatment of thromboembolic complications associated
with atrial fibrillation and/or cardiac valve
replacement (1)
Reduction in the risk of death, recurrent myocardial infarction, and
thromboembolic events such as stroke or systemic
embolization after myocardial infarction (1)
LIMITATIONS OF USE
Warfarin sodium tablets, USP have no direct effect on an established
thrombus, nor does it reverse ischemic tissue
damage. (1)
DOSAGE AND ADMINISTRATION
Individualize dosing regimen for each patient, and adjust based on INR
response. (2.1, 2.2)
Knowledge of genotype can inform initial dose selection. (2.3)
Monitoring: Obtain daily INR determinations upon initiation until
stable in the therapeutic range. Obtain subsequent
INR determinations every 1 to 4 weeks. (2.4)
Review conversion instructions from other anticoagulants. (2.8)
DOSAGE FORMS AND STRENGTHS
Scored tablets: 1, 2, 2.5, 3, 4, 5, 6, 7.5, or 10 mg (3)
CONTRAINDICATIONS
Pregnancy, except in women with mechanical heart valves (4, 5.5, 8.1)
Hemorrhagic tendencies or blood dyscrasias (4))
Recent or contemplated surgery of the ce